PD-L1和PD-1在胃癌组织中的表达及其临床意义-吴圣

[e-mail]-1PD-L1-1PD-1。1517420PD-L1PD-1。PD-L1PD-160.93%38.41%PD-L1PD-182.43%87.84%。PD-L1PD-1。PD-L1pTNM、、P＜0.05PD-1。PD-L1PD-1PD-L1PD-L1/PD-1。PD-L1PD-1Ｒ735．2A1000－1492201506－0821－05。。520%～25%1。、。2T。B7-1programmeddeathligand1PD-L1B7-H1B7。3PD-L1PD-L1-1programmeddeath1PD-1。PD-1CD28/CTLA-4TB。PD-L1/PD-1T、T、。PD-L1PD-14PD-L1PD-1。11．1200915120＞5cm。。1104126～7760。≤5cm115＞5cm36。Lauren103408。100483。AJCC2002TNM5Ⅰ～Ⅱ88Ⅲ～Ⅳ63。7477。8143。1．2PV-6000。4μm3%10minPBS35minpH6．020minPBS35minPD-11∶200PD-L1Abcam1∶2004℃PBS35minPV-600050·128·ActaUniversitatisMedicinalisAnhui2015Jun506μl20minPBS35min100μlDAB3～5min。1min。1．32。PD-L1PD-1。PD-L16。5×4000123≤10%110%～50%2＞50%3。≥3。。PD-15×400100PD-1PD-1。PD-1PD-1PD-1。1．4SPSS17．0PD-L1PD-1χ2。22．1PD-L1PD-1PD-L160.93%92/151。59.60%90/15134.44%52/151PD-10～5014.88±4.4914.88＞14.8838.41%58/15120PD-L1PD-1。1。PD-L1PD-182.43%746187.84%74652。2．2PD-L1PD-1χ2PD-L1PD-1χ2=2.010PD-L1PD-1χ2=0.2381。1PD-L1PD-1nPD-1nPD-L1－+PPD-L1－+P－9365280．15639540．626+58342422362．3PD-L1PD-1PD-L1pTNMP＜0.05、P＜0.01、P＜0.01P＜0.05。PD-L1pTNMP＜1PD-L1PD-1PV-6000×400APD-L1BPD-L1CPD-112·228·ActaUniversitatisMedicinalisAnhui2015Jun5062PD-L1PD-1PV-6000×400APD-L1BPD-10.05、P＜0.01P＜0.05。PD-12。3PD-L19q24290IsVIgC、C。7、、、、、PD-L1。PD-1IgVI288。TPD-18。PD-L1PD-19PD-L1PD-110PD-L12PD-L1PD-1nnPD-L1－+PPD-L1－+PPD-1－+P＜607032380．21648220．47043270．970≥608129525130503111050600．05970400．41468420．92541113029122516、2891917110．68315136827410．499472139290．192、、55253035203916cm≤511549660．32271440．05169460．473＞53612242882412pTNMⅠ～Ⅱ8842460．03064240．02954340．946Ⅲ～Ⅳ631944352839241004060633760404819290．64434140．64332160．4403212112Lauren4017233010251510341620．94467360．12464390．7868352644291910218209289190．0092080．43815130．490943361583658367739380．00958190．01047300．8877422524133462814361820．01797460．01390530．1508082635·328·ActaUniversitatisMedicinalisAnhui2015Jun506PD-1。PD-L1PD-1PD-L1PD-1。PD-L1PD-1PD-L1PD-L1PD-L1。PD-L1PD-1PD-1PD-L1PD-1PD-1PD-L111。PD-L1PD-1。PD-L1、PD-L1PD-1。12PD-L1。Wangetal1381COXPD-L1。PD-L1。PD-L1PD-1TT。PD-L1/PD-1。PD-L1。1MeyerHJWilkeH．TreatmentstrategiesingastriccancerJ．DtschArzteblInt201110841698－706．2FerroneSWhitesideTL．TumormicroenvironmentandimmuneescapeJ．SurgOncolClinNAm2007164755－74．3MalaspinaTSGasparotoTHCostaMＲetal．Enhancedpro-grammeddeath1PD-1andPD-1ligandPD-L1expressioninpatientswithactiniccheilitisandoralsquamouscellcarcinomaJ．CancerImmunolImmunother2011607965－74．4KonishiJYamazakiKAzumaMetal．B7-H1expressiononnon-smallcelllungcancercellsanditsrelationshipwithtumor-in-filtratinglymphocytesandtheirPD-1expressionJ．ClinCancerＲes200410155094－100．5GreeneFrederickLed．AJCCcancerstagingmanualM．SpringerScience＆BusinessMedia2002．6MuCYHuangJAChenYetal．HighexpressionofPD-L1inlungcancermaycontributetopoorprognosisandtumorcellsim-muneescapethroughsuppressingtumorinfiltratingdendriticcellsmaturationJ．MedOncol2011283682－8．7KantekureKYangYＲaghunathPetal．ExpressionpatternsoftheimmunosuppressiveproteinsPD-1/CD279andPD-L1/CD274atdifferentstagesofcutaneousT-celllymphoma/mycosisfungoidesJ．AmJDermatopathol2012341126－8．8ShiFShiMZengZetal．PD-1andPD-L1upregulationpro-motesCD8+T-cellapoptosisandpostoperativerecurrenceinhepatocellularcarcinomapatientsJ．IntJCancer20101284877－96．9．B7-H1PD-1J．2008303192－5．10．PD-L1PD-1J．20112791551－3．11KlineJGajewskiTF．ClinicaldevelopmentofmAbstoblockthePD1pathwayasanimmunotherapyforcancerJ．CurrOpinIn-vestigDrugs201011121354－9．12GadiotJHooijkaasAIKaiserADetal．OverallsurvivalandPD-L1expressioninmetastasizedmalignantmelanomaJ．Canc-er2011117102192－201．13WangLMaQChenXetal．ClinicalsignificanceofB7-H1andB7-1expressionsinpancreaticcarcinomaJ．WorldJSurg20103451059－65．ExpressionandclinicalsignificanceofPD-L1andPD-1ingastriccarcinomaWuShengShaoJingyiWangFangetalDeptofMedicalOncologyTheFirstAffiliatedHospitalofAnhuiMedicalUniversityHefei230022AbstractObjectiveToinvestigatethecorrelationbetweentheexpressionofcostimulatorymoleculeprogrammeddeathligand1PD-L1aswellasitsreceptorprogrammeddeath1PD-1ingastriccarcinomaandclinicopatho-·428·ActaUniversitatisMedicinalisAnhui2015Jun506logicfeatures．MethodsThestudycomprisedtumorsectionsfrom151gastriccancerpatientstreatedwithcurativeresection74matchedlymphnodesand20casesofadjacentnormaltissuescontrolswhichwereevaluatedforPD-L1andPD-1proteinexpressionbyimmunohistochemistry．ＲesultsPD-L1andPD-1expressionwereincreasedincancerscomparedtoadjacentnormaltissueswithpositiverateof60.93%and38.41%respectively.MeanwhileexpressionsofPD-L1andPD-1werehighlycorrelatedbetweentheprimarytumorsandmetastaticnodeswithcon-cordanceratesof82.43%and87.84%forPD-L1andPD-1respectively．PD-L1expressioningastriccarcinomawasnotcorrelatedwithPD-1expressioninlymphocyte．ExpressionofPD-L1wassignificantlycorrelatedwithsomeclinicopathologicfeaturesincludingstagedepthofinvasionlymphnodemetastasisandvascularmetastasisP＜0.05butnotPD-1．ConclusionPD-L1andPD-1areoverexpressedingastriccancertissues．PD-L1expres-sionplaysacriticalroleinthepathogenesisofhumangastriccancersuggestingthatitmightbeusedasanewbio-markertopred